Prioritising respiratory syncytial virus prevention in low-income and middle-income countries.
作者信息
Carbonell-Estrany Xavier, Simões Eric Af, Bont Louis J, Paes Bosco A
机构信息
Neonatology, Hospital Clinic, Barcelona 08036, Spain.
Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA; Department of Epidemiology, Center for Global Health, Colorado School of Public Health, Aurora, CO, USA.
出版信息
Lancet Glob Health. 2023 May;11(5):e655-e657. doi: 10.1016/S2214-109X(23)00165-1.
Abstract
摘要
相似文献
1
Prioritising respiratory syncytial virus prevention in low-income and middle-income countries.在低收入和中等收入国家将呼吸道合胞病毒预防列为优先事项。
Lancet Glob Health. 2023 May;11(5):e655-e657. doi: 10.1016/S2214-109X(23)00165-1.
2
New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants.新型呼吸道合胞病毒疫苗在中低收入国家的应用：对婴幼儿高发疾病具有潜在的成本效益影响。
BMC Med. 2023 May 15;21(1):177. doi: 10.1186/s12916-023-02883-x.
3
Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.呼吸道合胞病毒的季节性和低收入及中等收入国家婴儿被动免疫预防策略规划：建模研究。
Lancet Infect Dis. 2021 Sep;21(9):1303-1312. doi: 10.1016/S1473-3099(20)30703-9. Epub 2021 May 6.
4
Assessing the Full Burden of Respiratory Syncytial Virus in Young Infants in Low- and Middle-Income Countries: The Importance of Community Mortality Studies.评估中低收入国家婴幼儿呼吸道合胞病毒的全面负担：社区死亡率研究的重要性。
Clin Infect Dis. 2021 Sep 2;73(Suppl_3):S177-S179. doi: 10.1093/cid/ciab486.
5
RSV, Antibodies and the Developing World.呼吸道合胞病毒、抗体与发展中世界
Pediatr Infect Dis J. 2019 Jun;38(6S Suppl 1):S24-S27. doi: 10.1097/INF.0000000000002333.
6
Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries.预防小儿呼吸道合胞病毒病的药物策略的成本效益：用于低收入和中等收入国家的决策支持模型。
BMC Med. 2023 Apr 11;21(1):138. doi: 10.1186/s12916-023-02827-5.
7
Mathematical modelling of respiratory syncytial virus (RSV) in low- and middle-income countries: A systematic review.中低收入国家呼吸道合胞病毒（RSV）的数学模型：系统评价。
Epidemics. 2021 Jun;35:100444. doi: 10.1016/j.epidem.2021.100444. Epub 2021 Feb 22.
8
Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022.世界卫生组织关于评估中低收入国家呼吸道合胞病毒预防成本效益的技术磋商报告，2022 年 4 月 7-8 日。
Vaccine. 2023 Nov 22;41(48):7047-7059. doi: 10.1016/j.vaccine.2023.09.040. Epub 2023 Sep 28.
9
Respiratory syncytial virus circulation in seven countries with Global Disease Detection Regional Centers.呼吸道合胞病毒在全球疾病监测区域中心的七个国家的传播情况。
J Infect Dis. 2013 Dec 15;208 Suppl 3:S246-54. doi: 10.1093/infdis/jit515.
10
Importance of global surveillance for respiratory syncytial virus.全球呼吸道合胞病毒监测的重要性。
J Infect Dis. 2013 Dec 15;208 Suppl 3:S165-6. doi: 10.1093/infdis/jit484.
引用本文的文献
1
Genomic characterization and phylogenetic analysis of respiratory syncytial virus F gene in Sri Lanka: a comparative study.斯里兰卡呼吸道合胞病毒F基因的基因组特征及系统发育分析：一项比较研究
BMC Genom Data. 2025 Jul 29;26(1):52. doi: 10.1186/s12863-025-01343-0.
2
Global Trends and Attributable Risk Factors in the Disease Burden of Lower Respiratory Infections.下呼吸道感染疾病负担的全球趋势及可归因风险因素
Trop Med Infect Dis. 2025 Jun 26;10(7):180. doi: 10.3390/tropicalmed10070180.
3
Global, Regional, and National Burden of Pulmonary Fungal Infections 1990-2021.1990 - 2021年全球、区域和国家肺部真菌感染负担
Am J Respir Crit Care Med. 2025 Jun;211(6):1007-1017. doi: 10.1164/rccm.202410-2076OC.
4
Proof-of-principle of a technology transfer of a dried blood virus neutralisation assay to a Gavi-eligible country.将干血病毒中和试验技术转让给符合全球疫苗免疫联盟（Gavi）资格国家的原理验证。
BMJ Glob Health. 2025 Mar 4;10(3):e016916. doi: 10.1136/bmjgh-2024-016916.
5
Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.全球、区域和国家非 COVID-19 下呼吸道感染及病因的发病率、死亡率负担，1990-2021 年：来自 2021 年全球疾病负担研究的系统分析。
Lancet Infect Dis. 2024 Sep;24(9):974-1002. doi: 10.1016/S1473-3099(24)00176-2. Epub 2024 Apr 15.
6
Universal infant immunisation against respiratory syncytial virus and European inequalities: the pandemics lesson has not been learnt.针对呼吸道合胞病毒的普遍婴儿免疫接种与欧洲的不平等现象：尚未吸取大流行的教训。
Lancet Reg Health Eur. 2023 Oct 11;34:100753. doi: 10.1016/j.lanepe.2023.100753. eCollection 2023 Nov.
7
Wastewater-based surveillance identifies start to the pediatric respiratory syncytial virus season in two cities in Ontario, Canada.基于废水的监测确定了加拿大安大略省两个城市小儿呼吸道合胞病毒季节的开始。
Front Public Health. 2023 Sep 26;11:1261165. doi: 10.3389/fpubh.2023.1261165. eCollection 2023.
8
Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic.儿科呼吸道合胞病毒相关住院治疗在 COVID-19 大流行之前和期间。
JAMA Netw Open. 2023 Oct 2;6(10):e2336863. doi: 10.1001/jamanetworkopen.2023.36863.
9
The road to approved vaccines for respiratory syncytial virus.呼吸道合胞病毒获批疫苗之路。
NPJ Vaccines. 2023 Sep 25;8(1):138. doi: 10.1038/s41541-023-00734-7.
本文引用的文献
1
Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries.确定低收入和中等收入国家预防和管理呼吸道合胞病毒下呼吸道感染的研究、宣传、政策及实施需求。
Front Pediatr. 2022 Nov 9;10:1033125. doi: 10.3389/fped.2022.1033125. eCollection 2022.
2
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.2019 年全球、区域和国家因呼吸道合胞病毒导致 5 岁以下儿童急性下呼吸道感染的疾病负担估计：系统分析。
Lancet. 2022 May 28;399(10340):2047-2064. doi: 10.1016/S0140-6736(22)00478-0. Epub 2022 May 19.
3
Pneumococcal conjugate vaccine implementation in middle-income countries.中等收入国家肺炎球菌结合疫苗的实施情况。
Pneumonia (Nathan). 2017 Mar 25;9:6. doi: 10.1186/s41479-017-0030-5. eCollection 2017.
Zotero 插件